MGRX (Mangoceuticals, Inc. Common Stock) Stock Analysis - News
Mangoceuticals, Inc. Common Stock (MGRX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGRX trades at $0.40 with a market cap of $6.87M and a P/E ratio of -0.19. MGRX moved +1.62% today. Year to date, MGRX is -48.49%; over the trailing twelve months it is -72.97%. Its 52-week range spans $0.16 to $7.66. Rallies surfaces MGRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in MGRX news today?
Mangoceuticals Seeks Global Patent for MGX-0024 in Over 150 Countries after 29,000-Bird Trial: Mangoceuticals filed a PCT international application on February 26, 2026 extending patent protection for its MGX-0024 antiviral feed and drinking water additive to over 150 countries. The application builds on results showing zero respiratory mortality across 29,000 birds in field trials and significant prophylactic benefit against H5N1 in controlled studies.
JOHNSTON EUGENE M sold 3.33K (~$3.88K) on Dec 15, 2025.
JOHNSTON EUGENE M sold 5.00K (~$5.97K) on Dec 9, 2025.
JOHNSTON EUGENE M sold 10.00K (~$11.28K) on Dec 5, 2025.
MGRX Analyst Consensus
MGRX analyst coverage data. Average price target: $0.00.
Common questions about MGRX
What changed in MGRX news today?
Mangoceuticals Seeks Global Patent for MGX-0024 in Over 150 Countries after 29,000-Bird Trial: Mangoceuticals filed a PCT international application on February 26, 2026 extending patent protection for its MGX-0024 antiviral feed and drinking water additive to over 150 countries. The application builds on results showing zero respiratory mortality across 29,000 birds in field trials and significant prophylactic benefit against H5N1 in controlled studies.
Does Rallies summarize MGRX news?
Yes. Rallies summarizes MGRX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is MGRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MGRX. It does not provide personalized investment advice.
